CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
Vesatolimod +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03060447
NCT03060447Phase 1Completed
CompareCT.gov

A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Gilead Sciences·interventional·Posted Feb 23, 2017·Updated Apr 21, 2021

In Brief

A Phase 1 clinical trial evaluating Vesatolimod, Placebo, and 1 other intervention for HIV-1 Infection. Completed, enrolled 25 participants across 6 sites.

Detailed Summary

The primary objective of this study is to evaluate the safety and tolerability of a 10-dose regimen of vesatolimod in HIV-1 infected controllers on antiretroviral treatment (ART) and during analytical treatment interruption (ATI) following vesatolimod dosing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 23, 2017
Enrollment StartMay 9, 2017
Primary CompletionFeb 13, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.4 years ago

Interventions

Vesatolimoddrug

Tablets Administered orally

Placebodrug

Tablets Administered orally

ARTdrug

ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.